Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -954 | -100 | -51 | 0 | 0 |
| Operating Income | -4M | -2M | -2M | -2M | -2M |
| EBITDA | -4M | -2M | -4M | 0 | 0 |
| Net Income | -4M | -2M | -4M | -2M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.00
+0.00% today
1Y Change
-20.32%
Window
Jun 23, 2025 → Jun 4, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 4, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RetinalGenix Technologies Inc. (RTGN) is a Healthcare stock with a market cap of $80.00M and listed on OTC. The stock last traded around $4.00 and down 20.3% across the available one-year price window (Jun 23, 2025 → Jun 4, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +45.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +45.8%, free cash flow +24.7% with operating margin 0.0% and ROIC 0.0%. Stock Foundry combines RTGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RTGN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RTGN Max Drawdown
-36.25%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RTGN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.1M
+4.8% YoY
Free Cash Flow
-$1.4M
-21.9% YoY
Revenue Growth
+0.0%
EPS Growth
+45.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -954 | -100 | -51 | 0 | 0 |
| Operating Income | -4M | -2M | -2M | -2M | -2M |
| EBITDA | -4M | -2M | -4M | 0 | 0 |
| Net Income | -4M | -2M | -4M | -2M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6K | 0 | 38 | 5K | 2K |
| Total Assets | 15K | 156 | 294 | 5K | 61K |
| Total Liabilities | 1M | 1M | 1M | 470K | 141K |
| Shareholder Equity | -1M | -1M | -1M | -465K | -80K |
| Total Debt | 57K | 507K | 49K | 73K | 0 |
| Net Debt | 50K | 507K | 49K | 68K | -2K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
-21.9% YoY
Capital Expenditures
3
Free Cash Flow
1M
-21.9% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
119.6%
Debt / Equity
-0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.